Japanese Patient and Physician Preferences for Systemic Therapy Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Discrete Choice Experiment

Japanese Patient and Physician Preferences for Systemic Therapy Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Discrete Choice Experiment - SANGO-HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030220517

Enrollment

210

Registered

2022-12-19

Start date

2022-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [Patients] 1.Japanese patient aged 18 years or older at the time of informed consent 2.Has HCC history and has undergone TACE within 5 years from the time of informed consent 3.Can understand written Japanese 4.Has undergone systemic therapy (for qualitative survey only) [Physicians] 1.Hepatologist with a Japanese medical license and enough experience treating HCC in Japan (i.e., average 5 patients / year in the last 3 years) 2.Can understand written Japanese

Exclusion criteria

Exclusion criteria: [Patients] Patient or family member residing with the patient works in pharmaceutical, medical, or market research industries [Physicians] None

Design outcomes

Primary

Measure	Time frame
-Preference weight (strength) given to each attribute with its 95% confidence interval (CI) for patients and physicians. -Relative importance of the levels of each attribute.	—

Secondary

Measure	Time frame
Treatment preference weight relative to patients' and physicians' characteristics for each attribute and 95% CI.	—

Contacts

Public ContactAyako Fukui

AstraZeneca K.K.

ayako.fukui@astrazeneca.com+81-6-4802-3600

Outcome results